Media headlines about Asterias Biotherapeutics (NYSE:AST) have trended somewhat positive on Saturday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Asterias Biotherapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.2923869316975 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Asterias Biotherapeutics Inc (AST) Sees Significant Decline in Short Interest (americanbankingnews.com)
- BRIEF-Asterias Biotherapeutics opens additional clinical site for AST-OPC1 SCiStar study (reuters.com)
- Asterias Biotherapeutics Inc (AST) Given $8.88 Consensus Target Price by Analysts (americanbankingnews.com)
- Brokerages Expect Asterias Biotherapeutics Inc (AST) Will Announce Quarterly Sales of $1.50 Million (americanbankingnews.com)
AST has been the topic of a number of recent analyst reports. Zacks Investment Research raised Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Monday, July 17th. HC Wainwright set a $12.00 price objective on Asterias Biotherapeutics and gave the company a “buy” rating in a research note on Monday, June 12th.
Asterias Biotherapeutics (AST) opened at 3.35 on Friday. The company’s market capitalization is $167.43 million. The company has a 50 day moving average price of $3.37 and a 200-day moving average price of $3.38. Asterias Biotherapeutics has a 52 week low of $2.65 and a 52 week high of $5.80.
Asterias Biotherapeutics (NYSE:AST) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). Asterias Biotherapeutics had a negative return on equity of 86.25% and a negative net margin of 2,762.03%. The business had revenue of $0.32 million for the quarter, compared to the consensus estimate of $1.25 million. On average, equities analysts anticipate that Asterias Biotherapeutics will post ($0.61) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/08/26/asterias-biotherapeutics-ast-receives-daily-media-impact-score-of-0-08.html.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
